Biotech firm Prime Medicine valued at $1.8 bln in strong debut
20/10/2022 17:39
Oct 20 (Reuters) - Biotechnology firm Prime Medicine PRME.O notched a valuation of about $1.8 billion in its Nasdaq debut on Thursday, after its shares opened nearly 12% above their offer price. (Reporting by Manya Saini in Bengaluru; Editing by Maju Samuel) ((Manya.Saini@thomsonreuters.com;))
Recent news on Prime Medicine
See all newsBrief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Prime Medicine Q2 net loss narrows on lower expenses
Brief: Prime Medicine, Inc. Q2 EPS USD -0.24
Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease